Logo image of IDXX

IDEXX LABORATORIES INC (IDXX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IDXX - US45168D1046 - Common Stock

714.1 USD
-3.37 (-0.47%)
Last: 12/5/2025, 8:00:01 PM
714.1 USD
0 (0%)
After Hours: 12/5/2025, 8:00:01 PM
Fundamental Rating

7

Overall IDXX gets a fundamental rating of 7 out of 10. We evaluated IDXX against 188 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IDXX a very profitable company, without any liquidiy or solvency issues. IDXX has a decent growth rate and is not valued too expensively. This makes IDXX very considerable for quality investing!


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

In the past year IDXX was profitable.
In the past year IDXX had a positive cash flow from operations.
Each year in the past 5 years IDXX has been profitable.
In the past 5 years IDXX always reported a positive cash flow from operatings.
IDXX Yearly Net Income VS EBIT VS OCF VS FCFIDXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

Looking at the Return On Assets, with a value of 30.34%, IDXX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
IDXX's Return On Equity of 65.81% is amongst the best of the industry. IDXX outperforms 100.00% of its industry peers.
With an excellent Return On Invested Capital value of 40.25%, IDXX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for IDXX is significantly above the industry average of 8.78%.
The last Return On Invested Capital (40.25%) for IDXX is above the 3 year average (35.08%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 30.34%
ROE 65.81%
ROIC 40.25%
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
IDXX Yearly ROA, ROE, ROICIDXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

IDXX's Profit Margin of 24.65% is amongst the best of the industry. IDXX outperforms 95.24% of its industry peers.
IDXX's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 31.34%, IDXX belongs to the best of the industry, outperforming 98.94% of the companies in the same industry.
IDXX's Operating Margin has improved in the last couple of years.
IDXX's Gross Margin of 61.72% is fine compared to the rest of the industry. IDXX outperforms 62.43% of its industry peers.
IDXX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 31.34%
PM (TTM) 24.65%
GM 61.72%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
IDXX Yearly Profit, Operating, Gross MarginsIDXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

8

2. Health

2.1 Basic Checks

IDXX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, IDXX has less shares outstanding
IDXX has less shares outstanding than it did 5 years ago.
The debt/assets ratio for IDXX has been reduced compared to a year ago.
IDXX Yearly Shares OutstandingIDXX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IDXX Yearly Total Debt VS Total AssetsIDXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

IDXX has an Altman-Z score of 23.86. This indicates that IDXX is financially healthy and has little risk of bankruptcy at the moment.
IDXX has a better Altman-Z score (23.86) than 96.30% of its industry peers.
The Debt to FCF ratio of IDXX is 1.04, which is an excellent value as it means it would take IDXX, only 1.04 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.04, IDXX belongs to the best of the industry, outperforming 91.01% of the companies in the same industry.
IDXX has a Debt/Equity ratio of 0.53. This is a neutral value indicating IDXX is somewhat dependend on debt financing.
The Debt to Equity ratio of IDXX (0.53) is comparable to the rest of the industry.
Although IDXX does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 1.04
Altman-Z 23.86
ROIC/WACC4.42
WACC9.11%
IDXX Yearly LT Debt VS Equity VS FCFIDXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 1.18 indicates that IDXX should not have too much problems paying its short term obligations.
IDXX has a worse Current ratio (1.18) than 83.07% of its industry peers.
IDXX has a Quick Ratio of 1.18. This is a bad value and indicates that IDXX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of IDXX (0.87) is worse than 81.48% of its industry peers.
IDXX does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.18
Quick Ratio 0.87
IDXX Yearly Current Assets VS Current LiabilitesIDXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.16% over the past year.
IDXX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.18% yearly.
IDXX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.39%.
Measured over the past years, IDXX shows a quite strong growth in Revenue. The Revenue has been growing by 10.12% on average per year.
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%

3.2 Future

The Earnings Per Share is expected to grow by 13.81% on average over the next years. This is quite good.
Based on estimates for the next years, IDXX will show a quite strong growth in Revenue. The Revenue will grow by 9.18% on average per year.
EPS Next Y16.93%
EPS Next 2Y14.43%
EPS Next 3Y14.3%
EPS Next 5Y13.81%
Revenue Next Year10.46%
Revenue Next 2Y9.62%
Revenue Next 3Y9.46%
Revenue Next 5Y9.18%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
IDXX Yearly Revenue VS EstimatesIDXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B
IDXX Yearly EPS VS EstimatesIDXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10 20 30

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 56.63, IDXX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, IDXX is valued a bit cheaper than 68.78% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.46. IDXX is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 48.48, which means the current valuation is very expensive for IDXX.
69.84% of the companies in the same industry are more expensive than IDXX, based on the Price/Forward Earnings ratio.
IDXX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 36.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 56.63
Fwd PE 48.48
IDXX Price Earnings VS Forward Price EarningsIDXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

68.78% of the companies in the same industry are more expensive than IDXX, based on the Enterprise Value to EBITDA ratio.
73.02% of the companies in the same industry are more expensive than IDXX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 60.65
EV/EBITDA 39.64
IDXX Per share dataIDXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of IDXX may justify a higher PE ratio.
IDXX's earnings are expected to grow with 14.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.34
PEG (5Y)3.11
EPS Next 2Y14.43%
EPS Next 3Y14.3%

0

5. Dividend

5.1 Amount

IDXX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

IDEXX LABORATORIES INC

NASDAQ:IDXX (12/5/2025, 8:00:01 PM)

After market: 714.1 0 (0%)

714.1

-3.37 (-0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-03 2025-11-03/bmo
Earnings (Next)02-02 2026-02-02/amc
Inst Owners94.91%
Inst Owner Change-0.98%
Ins Owners0.21%
Ins Owner Change2.58%
Market Cap57.02B
Revenue(TTM)4.17B
Net Income(TTM)1.03B
Analysts80.95
Price Target773.18 (8.27%)
Short Float %2.14%
Short Ratio3.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)10.84%
PT rev (3m)11.82%
EPS NQ rev (1m)0.4%
EPS NQ rev (3m)1.8%
EPS NY rev (1m)2.24%
EPS NY rev (3m)2.34%
Revenue NQ rev (1m)0.37%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)1.25%
Revenue NY rev (3m)1.25%
Valuation
Industry RankSector Rank
PE 56.63
Fwd PE 48.48
P/S 13.68
P/FCF 60.65
P/OCF 52.41
P/B 36.52
P/tB 55.21
EV/EBITDA 39.64
EPS(TTM)12.61
EY1.77%
EPS(NY)14.73
Fwd EY2.06%
FCF(TTM)11.77
FCFY1.65%
OCF(TTM)13.63
OCFY1.91%
SpS52.19
BVpS19.55
TBVpS12.93
PEG (NY)3.34
PEG (5Y)3.11
Graham Number74.48
Profitability
Industry RankSector Rank
ROA 30.34%
ROE 65.81%
ROCE 61.18%
ROIC 40.25%
ROICexc 43.77%
ROICexgc 56.25%
OM 31.34%
PM (TTM) 24.65%
GM 61.72%
FCFM 22.56%
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
ROICexc(3y)39.8%
ROICexc(5y)41.54%
ROICexgc(3y)51.52%
ROICexgc(5y)54.7%
ROCE(3y)52.73%
ROCE(5y)50.92%
ROICexgc growth 3Y-5.99%
ROICexgc growth 5Y4.28%
ROICexc growth 3Y-3.86%
ROICexc growth 5Y4.07%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
F-Score8
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 1.04
Debt/EBITDA 0.57
Cap/Depr 105.48%
Cap/Sales 3.55%
Interest Coverage 250
Cash Conversion 75.23%
Profit Quality 91.51%
Current Ratio 1.18
Quick Ratio 0.87
Altman-Z 23.86
F-Score8
WACC9.11%
ROIC/WACC4.42
Cap/Depr(3y)119.67%
Cap/Depr(5y)117.13%
Cap/Sales(3y)3.91%
Cap/Sales(5y)3.89%
Profit Quality(3y)79.31%
Profit Quality(5y)83.23%
High Growth Momentum
Growth
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
EPS Next Y16.93%
EPS Next 2Y14.43%
EPS Next 3Y14.3%
EPS Next 5Y13.81%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
Revenue Next Year10.46%
Revenue Next 2Y9.62%
Revenue Next 3Y9.46%
Revenue Next 5Y9.18%
EBIT growth 1Y17.46%
EBIT growth 3Y6.64%
EBIT growth 5Y15.38%
EBIT Next Year33.13%
EBIT Next 3Y18.09%
EBIT Next 5Y14.77%
FCF growth 1Y38.31%
FCF growth 3Y7.86%
FCF growth 5Y21.3%
OCF growth 1Y31.08%
OCF growth 3Y7.13%
OCF growth 5Y15.14%

IDEXX LABORATORIES INC / IDXX FAQ

What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?

ChartMill assigns a fundamental rating of 7 / 10 to IDXX.


Can you provide the valuation status for IDEXX LABORATORIES INC?

ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.


Can you provide the profitability details for IDEXX LABORATORIES INC?

IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.


What is the valuation of IDEXX LABORATORIES INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 56.63 and the Price/Book (PB) ratio is 36.52.


Can you provide the expected EPS growth for IDXX stock?

The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 16.93% in the next year.